Guangdong Sunshine Lake Pharma

Sunshine Lake Pharma is a prominent Chinese pharmaceutical company and a key subsidiary of the HEC Group, specializing in the development and commercialization of innovative therapies and high-end generics. The company is widely recognized for its market-leading anti-viral portfolio, most notably its oseltamivir phosphate brand, Kewei, which dominates the Chinese influenza market. Beyond infectious diseases, Sunshine Lake Pharma maintains a robust R&D pipeline targeting metabolic disorders, oncology, and cardiovascular conditions. Its integrated capabilities encompass the entire value chain from drug discovery and clinical development to large-scale GMP manufacturing. The company actively pursues international expansion, with multiple products receiving approvals from the FDA and EMA.